Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.

NCT Number	NCT07132008
Lead Sponsor	First Affiliated Hospital of Guangxi Medical University Collaborators: The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of University of South China
Conditions	Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
Enrollment	94 participants
Start Date	2025-10-01
Primary Completion	2027-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-20